The quarterly results are the first to include sales of Eli Lilly’s new weight loss drug Zepbound, which won FDA approval in early November.
Source：https://www.cnbc.com/2024/02/06/eli-lilly-lly-earnings-q4-2023.html
Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue
ADVERTISEMENT